Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.39 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30284164 | 1.00 | MEN1 (0.49) | MEN1KMT2ATACR1OPRK1KCNQ2 | |
| SCHEMBL30284071 | 0.95 | MEN1 (0.44) | MEN1KMT2ATACR1OPRK1GPR142 | |
| SCHEMBL23972991 | 0.95 | MEN1 (0.44) | MEN1KMT2ATACR1OPRK1GPR142 | |
| SCHEMBL30284408 | 0.95 | MEN1 (0.46) | MEN1KMT2ATACR1OPRK1KCNQ2 | |
| SCHEMBL23972407 | 0.95 | MEN1 (0.46) | MEN1KMT2ATACR1OPRK1KCNQ2 | |
| SCHEMBL23972288 | 0.93 | KMT2A (0.47) | MEN1KMT2ATACR1OPRK1KCNQ2 | |
| SCHEMBL34464253 | 0.92 | MEN1 (0.46) | MEN1KMT2ATACR1OPRK1KCNQ2 | |
| SCHEMBL26670477 | 0.92 | MEN1 (0.46) | MEN1KMT2ATACR1OPRK1KCNQ2 | |
| SCHEMBL23973611 | 0.92 | MEN1 (0.39) | MEN1KMT2ATACR1CLPPMTHFD2 | |
| SCHEMBL23972456 | 0.92 | TRPV1 (0.40) | MEN1KMT2ATACR1GPR142CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | MEN1 3786/4885KMT2A 4196/4885TACR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.